Literature DB >> 14969778

Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy?

P Gorwood1.   

Abstract

Generalized anxiety disorder (GAD) and major depressive disorder (MDD) are the most common type of anxiety-mood comorbidity. Up to 80% of subjects with lifetime GAD also have a comorbid mood disorder during their lifetime. Many hypotheses have been raised to explain such high comorbidity. Pleiotropy, i.e. a single genetic mutation explains (apparently) different disorders, is one of them and is hereby reviewed. Importance and reliability of GAD and MDD comorbidity (1); Evidence in favour of co-aggregation of GAD and MDD within families (the risk of one disorder in a proband increasing the risk for the other in relatives) (2); substantial heredity for both disorders according to twin studies with evidence for genetic correlation of unity between the two disorders (3); existence of numerous mechanisms (4) potentially linking the two disorders to common vulnerability genes, are all in accordance with such a hypothesis. Some examples of potentially shared mechanisms (such as CRF dysregulation or abnormal transcription factors) and possible common vulnerability genes (for example, the serotonin transporter gene) are given to highlight the pleiotropy hypothesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969778     DOI: 10.1016/j.eurpsy.2003.10.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  31 in total

1.  The influence of sex and estrous cycle on QTL for emotionality and ethanol consumption.

Authors:  Geison S Izídio; Letícia C Oliveira; Lígia F G Oliveira; Elayne Pereira; Thaize D Wehrmeister; André Ramos
Journal:  Mamm Genome       Date:  2011-04-24       Impact factor: 2.957

Review 2.  Contextual conditioning in rats as an animal model for generalized anxiety disorder.

Authors:  Laura Luyten; Debora Vansteenwegen; Kris van Kuyck; Loes Gabriëls; Bart Nuttin
Journal:  Cogn Affect Behav Neurosci       Date:  2011-06       Impact factor: 3.282

3.  The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder.

Authors:  Young-Min Park; Do-Won Kim; Sangrae Kim; Chang-Hwan Im; Seung-Hwan Lee
Journal:  Psychopharmacology (Berl)       Date:  2010-11-06       Impact factor: 4.530

Review 4.  The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review.

Authors:  Frank Iorfino; Ian B Hickie; Rico S C Lee; Jim Lagopoulos; Daniel F Hermens
Journal:  BMC Psychiatry       Date:  2016-05-23       Impact factor: 3.630

Review 5.  Psychological and Behavioral Issues in the Management of Migraine in Children and Adolescents.

Authors:  William Qubty; Amy A Gelfand
Journal:  Curr Pain Headache Rep       Date:  2016-12

6.  Experiential Avoidance Predicts Persistence of Major Depressive Disorder and Generalized Anxiety Disorder in Late Adolescence.

Authors:  William H Mellick; James A Mills; Emily B Kroska; Chadi A Calarge; Carla Sharp; Lilian N Dindo
Journal:  J Clin Psychiatry       Date:  2019-10-22       Impact factor: 4.384

Review 7.  [Generalized anxiety disorder with comorbidity. Treatment with pregabalin].

Authors:  D Lauer; L Hölzel; M Hornyak
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

8.  Serotonin transporter and BDNF polymorphisms interact to predict trait worry.

Authors:  Keith Bredemeier; Christopher G Beevers; John E McGeary
Journal:  Anxiety Stress Coping       Date:  2014-04-25

9.  Impact of Comorbid Depressive Disorders on Subjective and Physiological Responses to Emotion in Generalized Anxiety Disorder.

Authors:  Saren H Seeley; Douglas S Mennin; Amelia Aldao; Katie A McLaughlin; Jonathan Rottenberg; David M Fresco
Journal:  Cognit Ther Res       Date:  2015-12-12

10.  Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness.

Authors:  Maureen P Boyle; Benedict J Kolber; Sherri K Vogt; David F Wozniak; Louis J Muglia
Journal:  J Neurosci       Date:  2006-02-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.